Sachin Tyagi¹*, Navdeep Baswal², Rahul K Singh², Ashok Kumar³, Navneet Sharma³ and Akshat Uniyal⁴

¹Department of Microbiology, School of Life Sciences and Technology, IIMT University, Meerut, UP, India

*Corresponding Author: Sachin Tyagi, Department of Microbiology, School of Life Sciences and Technology, IIMT University, Meerut, UP, India.

Received: June 23, 2023; Published: July 27, 2023

Abstract

Pathogenic RNA viruses continuously evading the human populations, and most prevailing in the last three decades. There are some notably examples as Human Immunodeficiency Virus, Ebola-virus and SARS-CoV2 globally emerged as threatened majorly to the public health concern from more than 180 known RNA virus species that may infect humans. New species and new variants of existing RNA viruses, being reported continuously, on average among these species, 89 percent considered the zoonotic origin. Therefore, we required more scientific understanding of the regular appearance or re-emergence of fatal pathogenic RNA viruses had been a profound impact on human health. The Current review provides the current status of RNA viruses, mainly emphasis on the host-virus relationship mapping, mechanism of adaptation in disease and strategies to control them and available vaccines against them. Conclusively, we required extensive research programs in the specialized antiviral drug programming interfaces would allow us to remain prepared until the next virus appears.

 Keywords- SARS-CoV2; Pathogenic RNA Viruses; Vaccines

References

1. Roberts M., et al. “Challenges in modelling the dynamics of infectious diseases at the wildlife-human interface”. Epidemics 37 (2021): 100523.
2. Cutler SJ., et al. “Public health threat of new, reemerging, and neglected zoonoses in the industrialized world”. Emerging Infectious Diseases (2010): 1-7.
3. Kuhn JH. “Virus Taxonomy”. Encyclopedia of Virology (2021): 28-37.
4. Peck KM and Lauring AS. “Complexities of Viral Mutation Rates. Sullivan CS, editor”. Journal of Virology (2018): 92.
5. Weaver SC and Forrester NL. “Chikungunya: Evolutionary history and recent epidemic spread”. Antiviral Research (2015): 32-39.
6. Woolhouse MEJ., et al. “Assessing the epidemic potential of RNA and DNA viruses”. Emerging Infectious Diseases 22 (2016): 2037-2044.
7. Enard D., et al. “Ancient RNA virus epidemics through the lens of recent adaptation in human genomes”. The Royal Society 375 (2020): 20190575.
8. Robson F., et al. “Coronavirus RNA Proofreading: Molecular Basis and Therapeutic Targeting”. Molecular Cell 79 (2020): 710-727.
9. Simon-Loriere E and Holmes EC. “Why do RNA viruses recombine?” Nature Reviews Microbiology 9 (2011): 617-626.
10. Smith EC., et al. “Thinking Outside the Triangle: Replication Fidelity of the Largest RNA Viruses”. Annual Review of Virology 1 (2014): 111-132.
11. Saha RP., et al. “Repurposing Drugs, Ongoing Vaccine, and New Therapeutic Development Initiatives Against COVID-19”. Frontiers in Pharmacology (2020).
12. Holmes EC. “What can we predict about viral evolution and emergence?” Current Opinion in Virology (2013): 180-184.
13. Holmes EC. “The Expanding Virosphere”. Cell Host Microbe 20 (2016): 279-280.
14. Trifonov V and Rabadan R. “Frequency Analysis Techniques for Identification of Viral Genetic Data. Lipkin WI, editor”. MBio (2010): 1.
15. Murray CJL., et al. “Global, regional, and national incidence and mortality for HIV, tuberculosis, and malaria during 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013”. Lancet 384 (2014): 1005-1070.
16. Jacob ST., et al. “Ebola virus disease”. Nature Reviews Disease Primers 6 (2020): 13.
17. Peng J., et al. “The Origin of Novel Avian Influenza A (H7N9) and Mutation Dynamics for Its Human-To-Human Transmissible Capacity. Stambas J, editor”. PLoS One 9 (2014): e93094.
18. Marshall N., et al. “Influenza Virus Reassortment Occurs with High Frequency in the Absence of Segment Mismatch. Basler CF, editor”. PLoS Pathogens 9 (2013): e1003421.
19. Lu L., et al. “Reassortment patterns of avian influenza virus internal segments among different subtypes”. BMC Ecology and Evolution 14 (2014): 16.
20. Holmes EC., et al. “Whole-genome analysis of human influenza A virus reveals multiple persistent lineages and reassortment among recent H3N2 viruses. Levin S, editor”. PLoS Biology 3 (2005): 1579-1589.
21. Treanor J. “Influenza Vaccine — Outmaneuvering Antigenic Shift and Drift”. The New England Journal of Medicine 350 (2004): 218-220.
22. Coltart CEM., et al. “The Ebola outbreak, 2013-2016: Old lessons for new epidemics”. Philosophical Transactions of the Royal Society B (2017): 20160297.
23. Fairhead J., et al. “Spillover or endemic? Reconsidering the origins of Ebola virus disease outbreaks by revisiting local accounts in light of new evidence from Guinea”. BMJ Global Health 6 (2021): e005783.
24. Andersen KG., et al. “The proximal origin of SARS-CoV-2”. Nature Medicine 26 (2020): 450-452.
25. World Health Organization. “WHO-convened global study of origins of SARS-CoV-2: China Part. COVID-19 Anim”. Interface Food Safety (2021).
26. Jayaweera M., et al. “Transmission of COVID-19 virus by droplets and aerosols: A critical review on the unresolved dichotomy”. Environmental Research 188 (2020): 109819.
27. Greenhalgh T., et al. “Ten scientific reasons in support of airborne transmission of SARS-CoV-2”. Lancet Elsevier (2021): 1603-1605.
28. Ge H., et al. “The epidemiology and clinical information about COVID-19”. European Journal of Clinical Microbiology and Infectious Diseases (2020): 1011-1019.
29. Liu P., et al. “Are pangolins the intermediate host of the 2019 novel coronavirus (SARS-CoV-2)?” PLoS Pathogen. Public Library of Science (2020): e1008421.
30. United Nations Environment Programme. “Zoonotic diseases and how to break the chain of transmission: A scientific assessment with key messages for policy-makers”. UN Environ. Program. (2020).
31. Petrikova I., et al. “COVID-19, wet markets, and planetary health”. Lancet Planet Health 4 (2020): e213-214.
32. Lin B., et al. “A better classification of wet markets is key to safeguarding human health and biodiversity”. Lancet Planet Health (2021): e386-394.
33. NIH NI of H. “What’s New | COVID-19 Treatment Guidelines”. Natl. Institutes Heal. USA (2022).
34. Ianevski A., et al. “Expanding the activity spectrum of antiviral agents”. Drug Discovery Today 24 (2019): 1224-1228.
35. Chaudhuri S., et al. “Innovation and trends in the development and approval of antiviral medicines: 1987-2017 and beyond”. Antiviral Research 155 (22018): 76-88.
36. De Clercq E and Li G. “Approved Antiviral Drugs over the Past 50 Years”. Clinical Microbiology Review 29 (2016): 695-747.
37. Geraghty RJ., et al. “Broad-spectrum antiviral strategies and nucleoside analogues”. Viruses (2021): 667.
38. Eberhardt KA., et al. “Ribavirin for the treatment of Lassa fever: A systematic review and meta-analysis”. International Journal of Infectious Diseases 87 (2019): 15-20.
39. Perales C., et al. “Resistance of hepatitis C virus to inhibitors: Complexity and clinical implications”. Viruses MDPI AG (2015): 5746-5766.
40. Warren T., et al. “Nucleotide Prodrug GS-5734 Is a Broad-Spectrum Filovirus Inhibitor That Provides Complete Therapeutic Protection Against the Development of Ebola Virus Disease (EVD) in Infected Non-human Primates”. Open Forum Infectious Diseases (2015): 2.
41. Lo MK., et al. “GS-5734 and its parent nucleoside analog inhibit Filo-, Pneumo-, and Paramyxoviruses”. Scientific Report 7 (2017): 43395.
42. WHO Solidarity Trial Consortium., et al. “Repurposed Antiviral Drugs for Covid-19 — Interim WHO Solidarity Trial Results”. The New England Journal of Medicine 384 (2021): 497-511.
43. Little SJ., et al. “Antiretroviral-Drug Resistance among Patients Recently Infected with HIV”. The New England Journal of Medicine 347 (2021): 385-394.
44. Taguwa S., et al. “Defining Hsp70 Subnetworks in Dengue Virus Replication Reveals Key Vulnerability in Flavivirus Infection”. Cell 163 (2015): 1108-1123.
45. Yuan S., et al. “SREBP-dependent lipidomic reprogramming as a broad-spectrum antiviral target”. Nature Communication 10 (2019): 1-15.
46. Barnes K. “Culturing poliovirus in cells”. Nature Research (2021).
47. Nascimento IP and Leite LCC. “Recombinant vaccines and the development of new vaccine strategies”. Brazilian Journal of Medical and Biological Research 45 (2012): 1102-1111.
48. Atherton MJ., et al. “Cancer immunology and canine malignant melanoma: A comparative review”. Veterinary Immunology and Immunopathology 169 (2016)15-26.
49. Leitner WW., et al. “DNA and RNA-based vaccines: principles, progress and prospects”. NIH Public Access 18 (1999): 765.
50. Lundstrom K. “RNA viruses as tools in gene therapy and vaccine development”. Genes (Basel) 10 (2019).
51. Monath TP., et al. “rVSVΔG-ZEBOV-GP (also designated V920) recombinant vesicular stomatitis virus pseudotyped with Ebola Zaire Glycoprotein: Standardized template with key considerations for a risk/benefit assessment”. Vaccine X 1 (2019): 100009.
52. Cate TR., et al. “Clinical Trials of Monovalent Influenza A/New Jersey/76 Virus Vaccines in Adults: Reactogenicity, Antibody Response, and Antibody Persistence”. Journal of Infectious Disease 136 (1977): S450-455.
53. Roldão A., et al. “Virus-like particles in vaccine development”. Expert Reviews in Vaccines 9 (2010): 1149-1176.
54. Buonaguro L., et al. “Virus-like particles as particulate vaccines”. Current HIV Research 8 (2010): 299-309.
55. Jain NK., et al. “Formulation and stabilization of recombinant protein based virus-like particle vaccines”. Advanced Drug Delivery Reviews 93 (2015): 42-55.
56. Nations Environment Programme U, Livestock Research Institute I. A Scientific Assessment with Key Messages for Policy-Makers A Special Volume of UNEP’s Frontiers Report Series PREVENTING THE NEXT PANDEMIC PREVENTING THE NEXT PANDEMIC Zoonotic diseases and how to break the chain of transmission (2020).
57. Nepstad D., et al. “Slowing Amazon deforestation through public policy and interventions in beef and soy supply chains”. Science (80-). American Association for the Advancement of Science 344 (2014)1118-123.
58. Rohr JR., et al. “Emerging human infectious diseases and the links to global food production”. Nature Sustainability 2 (2019)445-456.
59. Tensen L. “Under what circumstances can wildlife farming benefit species conservation?” Global Ecology Conservation 6 (2016): 286-298.
60. Hassell JM., et al. “Urbanization and Disease Emergence: Dynamics at the Wildlife-Livestock-Human Interface”. Trends in Ecology and Evolution 32 (2017): 55.
61. Muley D., et al. “Role of transport during outbreak of infectious diseases: Evidence from the past”. Sustain 12 (2020): 1-22.
62. Wertheim-Heck S., et al. “Food safety and nutrition for low-income urbanites: exploring a social justice dilemma in consumption policy”. 31 (2019): 397-420.
63. Evander M and Ahlm C. “Milder winters in northern Scandinavia may contribute to larger outbreaks of haemorrhagic fever virus”. Global Health Action 2 (2009).
64. Wells K and Clark NJ. “Host Specificity in Variable Environments”. Trends in Parasitology 35 (2019): 452-465.
65. Khan N., et al. “Explanation of Corona Virus Control Novel by Warm and Humid Seasons in the World”. SSRN Electronic Journal (2020).
66. Zinsstag J., et al. “Towards integrated surveillance-response systems for the prevention of future pandemics”. Infectious Diseases of Poverty 9 (2020): 140.
67. Carroll D., et al. “Preventing the next pandemic: the power of a global viral surveillance network”. British Medical Journal Publishing Group 372 (2021): n485.
68. Wille M., et al. “How accurately can we assess zoonotic risk?” PLOS Biology 19 (2021): e3001135.
69. Jia K and Mohamed K. “Evaluating the use of cell phone messaging for community Ebola syndromic surveillance in high risked settings in Southern Sierra”. African Health Science 15 (2015): 797.

Citation

Citation: Sachin Tyagi., et al. “RNA Viruses: A Review on Rapid Adaptation Potential and Globally Emerged Pandemics". Acta Scientific Microbiology 6.8 (2023): 57-72.

Copyright

Copyright: © 2023 Sachin Tyagi., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.